ArticleInternational immunopharmacology2022

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.

Seyed MohammadReza Hashemian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.